Q2 2018 13F Holders as of 30 Jun 2018
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
19.7M
-
Number of holders
-
341
-
Total 13F shares, excl. options
-
25.6M
-
Shares change
-
+887K
-
Total reported value, excl. options
-
$5.3B
-
Value change
-
+$188M
-
Put/Call ratio
-
0.67
-
Number of buys
-
163
-
Number of sells
-
-146
-
Price
-
$207.17
Significant Holders of LIGAND PHARMACEUTICALS INC - Common Stock (LGND) as of Q2 2018
376 filings reported holding LGND - LIGAND PHARMACEUTICALS INC - Common Stock as of Q2 2018.
LIGAND PHARMACEUTICALS INC - Common Stock (LGND) has 341 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 25.6M shares
.
Largest 10 shareholders include BlackRock Inc. (3.26M shares), VANGUARD GROUP INC (2.02M shares), WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (1.14M shares), JANUS HENDERSON GROUP PLC (927K shares), STATE STREET CORP (911K shares), AMERIPRISE FINANCIAL INC (765K shares), DEUTSCHE BANK AG\ (555K shares), VICTORY CAPITAL MANAGEMENT INC (537K shares), RENAISSANCE TECHNOLOGIES LLC (523K shares), and Bank of New York Mellon Corp (515K shares).
This table shows the top 341 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.